📣 VC round data is live. Check it out!

Brain+ Valuation Multiples

Discover revenue and EBITDA valuation multiples for Brain+ and similar public comparables like Clarent, Premier Health Of America, Omni Health, Binovi Technologies and more.

Brain+ Overview

About Brain+

Brain+ AS is a digital therapeutics company. It is focused on developing and commercializing solutions for dementia care and with a primary focus on Cognitive Stimulation Therapy (CST). The company has developed a set of Digital Medicine technologies. Its product pipeline includes CST Therapist Companion, and CST Home Companion; CST Home Care; CST for Mild Cognitive Impairment (MCI). The company is developing Ayla, a scalable dementia care platform that provides software-based therapy and care solutions designed to support individuals with dementia.


Founded

2012

HQ

Denmark

Employees

12

Financials (FY)

Revenue: -
Net Income: -

Market Cap

$461K

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Brain+ Stock Performance

Brain+ has current market cap of $461K.

Market Cap Evolution


Brain+'s stock price is $0.00.

Brain+ share price decreased by 70.8% in the last year.

See more trading valuation data for Brain+
Market CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$461K0.0%---70.8%-

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Brain+ Valuation Multiples

Brain+ Financial Valuation Multiples

As of June 2, 2026, Brain+ has market cap of $461K.

LTMLast FY202320242025202620272028

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Brain+ Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Valuation Multiples Across 230+ Verticals

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Clarent----
Premier Health Of America0.4x0.4x(12.3x)-
Omni Health----
Binovi Technologies----
Alternate Health----
1933 Industries1.0x-17.5x-
Medondo Holding3.8x-(5.6x)-
Monsenso2.0x-(5.9x)-

This data is available for Pro users. Sign up to see all Brain+ competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Brain+

When was Brain+ founded?Brain+ was founded in 2012.
Where is Brain+ headquartered?Brain+ is headquartered in Denmark.
How many employees does Brain+ have?As of today, Brain+ has over 12 employees.
Is Brain+ publicly listed?Yes, Brain+ is a public company listed on Nasdaq Copenhagen.
What is the stock symbol of Brain+?Brain+ trades under BRAINP ticker.
When did Brain+ go public?Brain+ went public in 2021.
Who are competitors of Brain+?Brain+ main competitors include Clarent, Premier Health Of America, Omni Health, Binovi Technologies, Alternate Health, 1933 Industries, Medondo Holding, Monsenso, Aino Health, Telemedycyna Polska.
What is the current market cap of Brain+?Brain+'s current market cap is $461K.
Is Brain+ profitable?No, Brain+ is not profitable.
How many companies Brain+ has acquired to date?Brain+ hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Brain+ has invested to date?Brain+ hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Brain+

Lists including Brain+

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial